{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:15:56Z","timestamp":1790500556630,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.anai.2015.04.014","type":"journal-article","created":{"date-parts":[[2015,5,8]],"date-time":"2015-05-08T12:38:34Z","timestamp":1431088714000},"page":"77-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience"],"prefix":"10.1016","volume":"115","author":[{"given":"Rachel G.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"MacRae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Karsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Santucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2015.04.014_bib1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2015.04.014_bib2","unstructured":"Novartis, Inc. Xolair (omalizumab) [product insert]. Dorval, Quebec, Canada;\u00a02011."},{"key":"10.1016\/j.anai.2015.04.014_bib3","series-title":"Center for Biologics Evaluation and Research. BLA STN 103976\/0, briefing document on safety (Genentech Inc)","year":"2003"},{"key":"10.1016\/j.anai.2015.04.014_bib4","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaci.2007.06.038","article-title":"Severe serum sickness-like syndrome after omalizumab therapy for asthma","volume":"120","author":"Pilette","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2015.04.014_bib5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S1081-1206(10)63560-0","article-title":"Characterization of an anaphylactoid reaction to omalizumab","volume":"96","author":"Dreyfus","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2015.04.014_bib6","unstructured":"US Food and Drug Administration. FDA proposes to strengthen label warning for Xolair [news release]. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2007\/ucm108850.htm. Published 2007. Accessed February 17,\u00a02015."},{"key":"10.1016\/j.anai.2015.04.014_bib7","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of\u00a0Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2015.04.014_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2011.04.010","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report","volume":"128","author":"Cox","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2015.04.014_bib9","first-page":"1","article-title":"Design of sample surveys to estimate the prevalence of rare diseases: three unbiased estimates","volume":"11","author":"Birnbaum","year":"1965","journal-title":"Vital Health Stat 2"},{"key":"10.1016\/j.anai.2015.04.014_bib10","unstructured":"Committee for Orphan Medicinal Products. Points to consider on the\u00a0calculation and reporting of the prevalence of a condition for orphan\u00a0designation. European Agency for the Evaluation of Medicinal Products. COMP\/436\/01. www.ema.europa.eu\/ema\/pages\/includes\/document\/open_document.jsp?webContentId=WC500003773. Published March 26,\u00a02002."}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120615002665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120615002665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:12:45Z","timestamp":1761052365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120615002665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1081120615002665"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2015.04.014","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2015.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}